I am a project director in the Neuroscience iMed at AstraZeneca, leading projects projects such as AZD5213 which is in phase IIa clinical development of both Tourette's Disorder and neuropathic pain, as well as others in the pre-clinical discovery phase. I earned my PhD from McGill University and joined AstraZeneca in 2005 to help grow the electrophysiology support for pre-clinical analgesia programs. I am also part of the Translational Sciences group within the Neuroscience iMed, whose mandate is to discover and implement biomarkers for clinical PoM studies and patient stratification strategies for various neurodegenerative, psychiatric and painful conditions.